0001567619-19-021875.txt : 20191119 0001567619-19-021875.hdr.sgml : 20191119 20191119164653 ACCESSION NUMBER: 0001567619-19-021875 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191115 FILED AS OF DATE: 20191119 DATE AS OF CHANGE: 20191119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ende Eric J CENTRAL INDEX KEY: 0001494386 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 191231825 MAIL ADDRESS: STREET 1: C/O MATINAS BIOPHARMA HOLDINGS, INC. STREET 2: 1545 ROUTE 206 SOUTH, SUITE 302 CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 doc1.xml FORM 4 X0306 4 2019-11-15 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001494386 Ende Eric J C/O AVADEL PHARMACEUTICALS PLC BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK DUBLIN L2 15 IRELAND 1 0 0 0 ADSs 2019-11-15 4 P 0 10000 4.9762 A 37900 D Stock Option (right to buy) 1.49 2029-05-22 ADSs 8057 8057 D Stock Option (right to buy) 2.03 2029-08-07 ADSs 60000 60000 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.94 to $4.98, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2). Includes 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 01/31/2019; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date. Options are exercisable as to 2,685 shares, 2,686 shares and 2,686 shares on May 22, 2020, May 22, 2021 and May 22, 2022, respectively. Options become exercisable as to 20,000 ADSs on each of the first three anniversaries after the 08/07/2019 grant date. /s/ Phillandas T. Thompson, as attorney-in-fact for Eric J. Ende 2019-11-19